# Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

> **NCT00308087** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 75 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Sargramostim (Leukine)
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00308087
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Terminated by sponsor due to low enrollment; see details below
- **Last updated:** 2013-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308087, "Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00308087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*